1. Home
  2. LXEH vs PPBT Comparison

LXEH vs PPBT Comparison

Compare LXEH & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lixiang Education Holding Co. Ltd.

LXEH

Lixiang Education Holding Co. Ltd.

HOLD

Current Price

$0.23

Market Cap

6.5M

Sector

Real Estate

ML Signal

HOLD

Logo Purple Biotech Ltd.

PPBT

Purple Biotech Ltd.

HOLD

Current Price

$0.53

Market Cap

6.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LXEH
PPBT
Founded
2001
2010
Country
China
Israel
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.5M
6.0M
IPO Year
2020
2014

Fundamental Metrics

Financial Performance
Metric
LXEH
PPBT
Price
$0.23
$0.53
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.7M
90.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.18
$0.46
52 Week High
$50.08
$3.00

Technical Indicators

Market Signals
Indicator
LXEH
PPBT
Relative Strength Index (RSI) 45.97 38.33
Support Level $0.18 N/A
Resistance Level $0.46 $0.64
Average True Range (ATR) 0.03 0.04
MACD -0.00 -0.00
Stochastic Oscillator 5.79 52.55

Price Performance

Historical Comparison
LXEH
PPBT

About LXEH Lixiang Education Holding Co. Ltd.

Lixiang Education Holding Co Ltd is a private primary and secondary education service provider in Lishui City, Zhejiang Province. Its private education services primarily include primary and middle school education from grade 1 to grade 9. The company also offers high school education services at its High School Divisions.

About PPBT Purple Biotech Ltd.

Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.

Share on Social Networks: